ArticleMycoses2026
Three-Dimensional Airway Reconstruction and Computational Spray Simulation to Guide Bronchoscopic Amphotericin B Delivery in Chronic Pulmonary Aspergillosis: An Exploratory Prospective Cohort Study With Historical Controls.
Article in Mycoses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo initially evaluate the feasibility and potential clinical value of high-resolution computed tomography (HRCT)-based three-dimensional (3D) airway reconstruction combined with computational spray simulation for guiding bronchoscopic amphotericin B delivery in patients with chronic pulmonary aspergillosis (CPA).
methodsThis multicenter, prospective cohort study with an expanded historical control was conducted. Patients in the prospective reconstruction cohort received HRCT-based 3D airway reconstruction combined with computational spray simulation to guide bronchoscopic amphotericin B delivery. Historical controls consisted of eligible CPA patients with complete clinical, imaging, treatment, adverse-event, and 6 month follow-up data who had received conventional bronchoscopic amphotericin B administration before implementation of the reconstruction-guided approach.
resultsA total of 10 patients in the reconstruction cohort and 30 historical controls were included. Baseline characteristics were generally comparable between groups, although fatigue was more frequent in the historical control cohort. At 6 months after treatment, the reconstruction cohort showed lower total St. George's respiratory questionnaire (SGRQ) scores than the historical control cohort. And SGRQ scores decreased significantly after treatment in each group, with a decrease of well over four points from baseline. More favourable clinical and radiographic responses and fewer adverse events were observed in the reconstruction cohort.
conclusionThe integrated reconstruction-guided strategy may provide a feasible strategy for optimizing bronchoscopic amphotericin B delivery in CPA. Given the historical-control design, small intervention cohort and potential residual confounding, these preliminary findings should be interpreted as exploratory and require confirmation in larger prospective controlled studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.